Costa, Eduardo L. V.
Alcala, Glasiele C.
Tucci, Mauro R.
Goligher, Ewan
Morais, Caio C.
Dianti, Jose
Nakamura, Miyuki A. P.
Oliveira, Larissa B.
Pereira, Sérgio M.
Toufen, Carlos Jr
Barbas, Carmen S. V.
Carvalho, Carlos R. R.
Amato, Marcelo B. P.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of extended lung protection during mechanical ventilation on lung recovery in patients with COVID-19 ARDS: a phase II randomized controlled trial
https://doi.org/10.1186/s13613-024-01297-z
Article History
Received: 25 January 2024
Accepted: 15 April 2024
First Online: 8 June 2024
Declarations
:
: The protocol was approved by the institutional review board of Incor/HC-FMUSP, University of Sao Paulo, Sao Paulo, Brazil (approval number 4.001.231). This trial was registered with ClinicalTrials.gov (number NCT04497454) on August 04, 2020. Informed consent was waived due to visiting constraints imposed by the pandemic.
: Not applicable.
: ELVC received consulting fees from Timpel, which manufactures a device used in this study. GCA received consulting fees from Timpel, which manufactures a device used in this study. MRT has no competing interests. EG has no competing interests. CCM received consulting fees from Timpel, which manufactures a device used in this study. JD has no competing interests. MAPN received consulting fees from Timpel, which manufactures a device used in this study. LBO has no competing interests. SMP has no competing interests. CTJr has no competing interests. CSVB has no competing interests. CRRC is a minority shareholder of Timpel, which manufactures a device used in this study. MBPA is a minority shareholder of Timpel, which manufactures a device used in this study.